3-dimensional *in vitro* **Models to Predict Relevant Toxicity or Pharmacological Effect in Human Lung**

Holger Behrsing, PhD, Director Vivek Patel, PhD, Toxicologist II *Respiratory Toxicology Program*





Agenda

- IIVS: Who we are and What we do
- Inhalation Exposures & Methods
- Test Systems & Endpoints
 - Reconstituted Human Airways
 - Human Precision-cut Lung slices (hPCLS)
- Advancing hPCLS
 - Long term culture
 - Cryopreservation & Retained Functionality








Institute for In Vitro Sciences

- IIVS was founded as a non-profit laboratory in 1997 to promote the use and acceptance of *in vitro* methods for toxicology
- We provide testing services to a variety of industries including cosmetic, household product, specialty chemical and pesticide manufacturers (fee-for-service)
- We use our knowledge to create education and outreach programs to promote the regulatory acceptance of these methods worldwide (contributions)


We are regarded as an independent technical authority by industry, animal protection and governments around the world



A Variety of Inhaled Materials



shutterstock.com + 1115231921



- Household products
 - cleaning agents, air care, upholstery and carpet care, "pesticides"
- Personal care products
 - sprays, powders, fragrances
- Occupational
 - institutional cleaning and care products, reactives, intermediates, volatiles
- Environmental
 - Smog, wildfire smoke, ozone
- Systemic exposures
 - Off target pharmaceutical effects




shutterstock.com + 659987572



Inhalation Exposure Complexity

Deposition of materials: Particle size and distribution



Deposition mechanisms:

- diffusion
- sedimentation
- inertial impaction
- interception
- electrostatic forces

all play a major or minor role

http://pubs.rsc.org/services/images/RSCpubs.ePlatform.Service.FreeContent.ImageService.svc/ImageService/Articleim age/2013/NR/c3nr01525d/c3nr01525d/f5.gif

Target Mass Deposition Estimates

Test Article	Respiratory	Estimated Deposition	Vitrocell® Cloud	
Characteristics	Parameters	in Lungs	Parameters	
 Particle/Aerosol Size Atmospheric Concentration Density Solubility 	 Breathing Rate Tidal Volume Minute Ventilation Alveolar Ventilation Regional Surface Area and Deposition Fraction 	 Total Test Article Inhaled per Defined Exposure Period Total Deposition per Unit Regional Surface Area Nasal cavity Trachea Bronchi Small airways Alveoli 	 Deposition Factor Nebulization Volume and Concentration Nebulizer size 	Targeted Mass Deposition

Estimated Total Deposition					
Parameters	1 hr	4 hr	8 hr		
Minute ventilation (L)	444	1776	3552		
Surface area deposited (cm ²)	14.69	14.69	14.69		
Deposition fraction	0.13	0.13	0.13		
TA concentration in air (μ g/L)	87.10	34.84	21.78		
Total TA inhaled (µg)	38672	61876	77345		
Total TA Deposition (µg/cm ²)	335.01	536.01	670.01		

References Applied (select):

- Corley et al., 2012 (CFD)
- Corley et al., 2018 (EPA report -Chlorothalonil)
- Asgharian et al., 2012 (MPPD)
- EPA, 2004 (Air Quality PM)

Additional Considerations:


- Mucociliary clearance
- Metabolism
- Diffusion

Exposures: Aqueous, Digital, & Aerosols

Aqueous

Conventional pipetting






- Material is solubilized or suspended in an aqueous medium or buffer
- Cons: non-aqueous soluble materials

Digital

Hewlett-Packard D300






- Biopattern dispensing: Entire exposure patterns can be *nanoliters* in volume
- Cons: Unique, emerging technology

Aerosol

VITROCELL® Cloud12



- Non-combusted & combusted aerosol generation
- Dosimetry
 - QCM
 - Surrogate analyte




- Cons: non-aqueous or miscible materials
- Setup/maintenance
- More labor intensive






2D Respiratory Cell Cultures




Cons: Primary cells are short live have a limited donor supply, but are more "normal-like" than lines. Lines are cancerous or immortalized, lacking normal attributes.

3D Respiratory Tract Models

Reconstructed Human Airways (RHuA)



Reconstructed Human Airways (RHuA)



Pros: 3D epithelium & multiple cell types. RHuA offer airway "lumen", mucous layer, & beating cilia. Long term cultures possible.

10

Cons: Closed system and no recruitment/systemic response. RHuA offer fewer cell types. Expensive & multi-week creation.


Choice of Test System & Endpoints

	Exposure Aqueous - Solvent - Aerosol Test System		aning Afri	
	Biomarkers/Events	2D Cells	3D RHuA	3D PCLS
Meleculer	Oxidative Stress	\checkmark	\checkmark	\checkmark
Molecular Initiating Events	DNA Binding/Strand Breaks	\checkmark	\checkmark	\checkmark
Initiating Events	Mitotoxicity	\checkmark	\checkmark	
	Cytotoxicity	\checkmark	\checkmark	\checkmark
Cellular	Viability	\checkmark	✓	\checkmark
Key Events	Macrophage Activation			\checkmark
	Cytokine/Chemokine Response	\checkmark	\checkmark	\checkmark
	Tight Junction Integrity		\checkmark	
	ECM Deposition			\checkmark
Tissue/Organ	Mucociliary Clearance		$\mathbf{\nabla}$	
Key Events	Goblet Cell Increase		\checkmark	
\setminus	Mucin Expression		$\mathbf{\nabla}$	
	Chronic Inflammation		\checkmark	\checkmark
	Chronic Tissue Health		\checkmark	\checkmark

☑ = unique to Model

IIVS & Respiratory NAMs

- IIVS was approached to develop NAMs for evaluating fragrance materials for respiratory irritation
- Respiratory Toxicology at IIVS has been active:
 - hosting workshops, participating in inter-lab technical exercises, presenting at international conferences, and serving on expert panels
- IIVS has been pursuing method development to address the need for identifying respiratory sensitizers and has recently formed a collaboration with RIFM



Respiratory Sensitization

Chary, A., Hennen, J., Klein, S.G. et al. Respiratory sensitization: toxicological point of view on the available assays. Arch Toxicol 92, 803–822 (2018).

Respiratory Sensitization Adverse Outcome Pathway

Molecular Properties Molecular Initiating Events

Key Events

Adverse Outcome

Structure and chemical/biological properties of the sensitizer Uptake and processing via exposure route (inhalation)

- Tight junction disruption (MIE1)
- Receptor mediated endocytosis) (MIE1)
- Unknown endocytosis (MIE3)


- Epithelial activation and alarmin response (KE1)
- DC activation (KE2)
- DC migration (KE3)
- T cell skewing (KE4)
- B cell isotype switching
- (KE5)

Clinical Outcome

- Serum IgE
- Basophil/mast cell activation
- Clinical symptoms

PCLS: Activated Macrophages

Anti-CD86 IHC



Control (72hr)

5 µg/mL LPS (72hr)


Multiplex Marker Upregulation



IIVS utilizes the **Luminex MagPix** and magnetic bead technology to multiplex and quantify marker levels from:

- Apical rinses
- Media
- Tissue lysates

Quartz silica induces marker levels without loss of viability in PCLS




Note: values above the highest standard were extrapolated by Luminex xPonent software

Advancing Human Precision-cut Lung Slices

Dr. Vivek Patel


Long Term Human PCLS Culture


Fresh Human PCLS can be maintained for weeks to evaluate long term changes.




Frozen Human PCLS are now on demand


- IIVS developed cryopreservation buffer for longer post-thaw cultures
- Air-liquid interface (ALI) and submerged cultures compared
- Viable macrophages identified (arrows)






Characterization of cryopreserved PCLS





Triton™ X-100-induced Cytotoxicity



19

LPS-induced Tissue Responses

25

20


4


Fold Change 5 E

1

0

D1






D8

技


D15

IL-8

Eresh Cryo



- LPS-induced IL-6, IL-8 and MCP-1 responses are observed through the 4 wk culture period
- Weak TIMP-1 and GRO-α response to LPS
- Efforts exploring consistency in responses are under way



Next Steps for hPCLS?

- Continue developing the application of hPCLS (fresh and frozen) for test material screening
 - Detection of sensitization vs irritation markers
 - Generation of the fibrosis phenotype
 - Evaluation of long-term effects (following single or repeat exposures)
 - Comparison of donor demographic-based responses
- Advocate standardization of hPCLS methodologies!
 - Consistent methods and data will position hPCLS as a candidate test system for regulatory testing applications

Acknowledgments

IIVS's staff, supporters, & collaborators!





Khalid Amin, MD (Pathologist, Assistant Professor, Uni. Minn.)



WWW.IIVS.Org Holger Behrsing, Ph.D.: <u>hbehrsing@iivs.org</u>



Vivek Patel, PhD

New Hire: Toxicologist I (immunology)

